ALLR — Allarity Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $17.93m
- -$0.33m
Annual cashflow statement for Allarity Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.07 | -26.6 | -16.1 | -11.9 | -24.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -1.38 | 6.07 | 1.12 | -4.33 | 7.54 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.445 | 5.57 | -0.328 | 3.35 | 0.063 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -7.25 | -14.9 | -16.8 | -12.7 | -17.4 |
| Capital Expenditures | -0.003 | 0 | -0.018 | — | -0.298 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 1 | 0.809 | 0 | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.003 | 1 | 0.791 | 0 | -0.298 |
| Financing Cash Flow Items | -0.223 | -2.04 | -0.8 | -0.002 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.03 | 33.8 | -1.31 | 11 | 36.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.23 | 19.3 | -17.5 | -1.86 | 19.4 |